Patient preferences for triple-class–exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study

To quantify patient preferences for attributes of novel treatments for triple-class–exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM). Using a discrete-choice experiment, we elicited preferences for 7 attributes: objective response rate (ORR), overall survival (OS), all-grade cytokine release syndrome risk, all-grade immune effector cell–associated neurotoxicity syndrome risk, serious infection risk (grade 3+), treatment administration, and initial hospitalization requirements. OS was the most important attribute (conditional relative importance [CRI] 32.0% for a 24-month increase), followed by serious infection risk (CRI 17.3% for avoiding a 60% risk), initial hospitalization requirements (CRI 15.0% for avoiding 14 days of initial hospitalization), and ORR (CRI 13.7% for a 38% increase). Based on differences between relative preference weights, fewer initial hospitalization days when starting treatment and off-the-shelf (vs. chimeric antigen receptor T [CAR T] cell–like) options were significantly preferred. Therapy decisions for patients with TCE RRMM should consider tradeoffs between efficacy, safety, and attributes related to treatment process and initial monitoring. Read the transcript Watch the video on Vimeo © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group